Grail (GRAL) Set to Announce Quarterly Earnings on Tuesday

Grail (NASDAQ:GRAL) will be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Investors interested in listening to the company’s conference call can do so using this link.

Grail (NASDAQ:GRAL) last issued its earnings results on Tuesday, August 13th. The company reported ($5.30) EPS for the quarter. The firm had revenue of $31.97 million during the quarter.

Grail Trading Down 2.8 %

GRAL stock opened at $14.48 on Monday. The firm’s 50 day moving average price is $13.62. Grail has a 12-month low of $12.33 and a 12-month high of $23.36.

Insider Transactions at Grail

In related news, major shareholder Chun R. Ding acquired 35,000 shares of Grail stock in a transaction that occurred on Thursday, October 3rd. The stock was acquired at an average price of $12.71 per share, for a total transaction of $444,850.00. Following the transaction, the insider now directly owns 3,558,655 shares of the company’s stock, valued at $45,230,505.05. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Grail news, CEO Robert P. Ragusa sold 123,454 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $14.02, for a total value of $1,730,825.08. Following the sale, the chief executive officer now owns 612,661 shares in the company, valued at approximately $8,589,507.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Chun R. Ding acquired 35,000 shares of Grail stock in a transaction dated Thursday, October 3rd. The shares were acquired at an average price of $12.71 per share, with a total value of $444,850.00. Following the completion of the transaction, the insider now owns 3,558,655 shares of the company’s stock, valued at approximately $45,230,505.05. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 58,829 shares of company stock worth $757,298.

Analyst Upgrades and Downgrades

Separately, Guggenheim started coverage on shares of Grail in a report on Thursday, October 17th. They issued a “neutral” rating for the company.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.